Bigul

Krishna Institute of Medical Sciences Ltd - 543308 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyKrishna Institute of Medical Sciences Ltd 2CIN NO.U55101TG1973PLC040558 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 184090989.22 4Highest Credit Rating during the previous FY AA- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Umashankar Mantha Designation: Company Secretary EmailId: cs@kimshospitals.com Name of the Chief Financial Officer: Vikas Maheshwari Designation: CFO EmailId: vikas@kimshospitals.com Date: 23/05/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
23-05-2022
Bigul

Krishna Institute of Medical Sciences Ltd - 543308 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Company intimates about newspaper advertisement of the Audited Financial Results of the company for the quarter and year ended 31st March, 2022 published on 20th May, 2022 in Financial Express (English) and Navatelangana (Telugu).
21-05-2022
Bigul

Q4FY22 Quarterly Result Announced for Krishna Institute of Medical Sciences Ltd.

Healthcare Facilities firm Krishna Institute of Medical Sciences declares Q4FY22 result: Q4 FY 21-22: Total Income saw an increase of 5% against Q4 of FY 21, standing at Rs. 3,805 million. Consolidated EBITDA for Q4 FY 22 stood at Rs. 1,218 million, a growth of 16% against Q4 FY 21. EBITDA margins expansion was driven by speciality mix and payor mix change over FY 21 last year and operation leverage Consolidated PAT of Rs. 833 million in Q4 FY22 a growth of 42% against EPS on diluted basis has increased to Rs.10.08 in Q4 FY 22 from Rs. 7.59 in Q4 FY 21 FY 21-22 Q4 FY21: Consolidated Total Income saw an increase of 25% to Rs 16,711 million against FY20-21 standing at Rs 13,401 million Consolidated EBITDA grew by 41% Rs. 5,360 million, mainly due to case mix, payer mix and cost optimisation EBIDTA Margin grew to 32.1% in FY22 from 28.4% in FY 21 primarily led by tighter cost control on operating expenses and operating leverage. Consolidated PAT saw an increase of 67% to Rs. 3,438 million against FY20-21 standing at Rs 2,055 million EPS on diluted basis has increased to Rs. 41.88 in FY 22 against FY 21 of Rs. 26.42 Result PDF
20-05-2022
Bigul

Krishna Institute of Medical Sciences Ltd - 543308 - Intimation Of Appointment Of Additional Independent Director On The Board Of Directors Of The Company

Krishna Institute of Medical Sciences Limited intimates the exchange about the Appointment of Women Independent Director.
19-05-2022
Bigul

Krishna Institute of Medical Sciences Ltd - 543308 - Announcement under Regulation 30 (LODR)-Investor Presentation

Krishna Institute of Medical Sciences Limited submits Investor Presentation
19-05-2022
Bigul

Krishna Institute of Medical Sciences Ltd - 543308 - Approval Of Audited Financial Results For The Quarter And Year Ended 31St March, 2022

Company submits Audited Financial Results for the Quarter and year ended 31st March, 2022
19-05-2022
Bigul

Krishna Institute of Medical Sciences Ltd - 543308 - Board Meeting Outcome for Outcome Of Board Meeting

Outcome of Board Meeting held on 19th May 2022 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
19-05-2022
Bigul

Krishna Institute of Medical Sciences Ltd - 543308 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Dr. Bhaskara Rao Bollineni - Founder & Managing Director, Dr. Abhinay Bollineni - Executive Director and CEO, and Mr. Vikas Maheshwari - Chief Financial Officer, would participate in a conference call with analysts and investors, being hosted by IIFL Securities on Friday 20th May, 2022, at 9:00 am IST, to discuss the company's business strategy and outlook post the declaration of Q4FY22 financial results.
17-05-2022
Next Page
Close

Let's Open Free Demat Account